Safety and Efficacy of 90Y Ibritumomab Tiuxetan (Zevalin®) for Untreated FollicularNon-Hodgkin’s Lymphoma (FL) Patients, An Italian Cooperative Study

Abstract 100▪▪This icon denotes a clinically relevant abstract 90Y ibritumomab tiuxetan (Zevalin®) combines the targeting advantage of monoclonal antibody with the radiosensitivity of FL. Previous studies showed that Zevalin resulted safe and highly effective in relapsed/refractory indolent NHL, irr...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2011-11, Vol.118 (21), p.100-100
Main Authors: Pica, G., Nati, S., Vitolo, Umberto, Galimberti, Sara, Zinzani, Pier Luigi, Cascavilla, Nicola, Petrini, Mario, Carella, A.M.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract 100▪▪This icon denotes a clinically relevant abstract 90Y ibritumomab tiuxetan (Zevalin®) combines the targeting advantage of monoclonal antibody with the radiosensitivity of FL. Previous studies showed that Zevalin resulted safe and highly effective in relapsed/refractory indolent NHL, irrespective to prior treatment with rituximab. Based on these results, we designed a multicenter trial to evaluate the safety and the efficacy of “upfront” single-agent Zevalin in FL. The primary endpoint was the incidence of responses in terms of overall remission rate (ORR) and complete remissions (CR). The secondary endpoints were the treatment safety by monitoring hematology and biochemistry parameters as well as adverse events. Fifty patients, with a median age of 59 years (range, 35–81), were treated. Forty-eight percent had bone marrow involvement (
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V118.21.100.100